The antitumor drugs camptothecin and an anilinoacridine, 4'-(9-acridinylamino)-methanesulfon-manisidide (mAMSA), which act on DNA topoisomerase I and H, respectively, are shown to inhibit the growth of Saccharomyces cerevisiae mutants selected for their permeability to other inhibitors. In addition to growth inhibition, these drugs induce high levels of homologous recombination and induce the expression of a DNA damage-inducible gene DIN3. Cytotoxicity of the drugs is more pronounced in strains that also carry a rad52 mutation. An analog of mAMSA, 4'-(9-acridinylamino)-methanesulfon-o-anisidide (oAMSA), which is ineffective as an inhibitor of DNA topoisomerase II in mammalian cells, is also ineffective in eliciting physiological responses in these yeast strains. A variety of antitumor chemotherapeutics have been shown recently to target the DNA topoisomerases (for review, see refs. 1-5). Their pharmacological effects correlate well with their effectiveness in trapping a class of complexes between DNA and DNA topoisomerases, termed the cleavable complexes, which are characterized by their conversion to DNAprotein covalent complexes upon their exposure to a protein denaturant (for review, see refs. 6-8).
cerevisiae mutants selected for their permeability to other inhibitors. In addition to growth inhibition, these drugs induce high levels of homologous recombination and induce the expression of a DNA damage-inducible gene DIN3. Cytotoxicity of the drugs is more pronounced in strains that also carry a rad52 mutation. An analog of mAMSA, 4'-(9-acridinylamino)-methanesulfon-o-anisidide (oAMSA), which is ineffective as an inhibitor of DNA topoisomerase II in mammalian cells, is also ineffective in eliciting physiological responses in these yeast strains. The physiological effects of camptothecin, but not those of mAMSA, disappear if the TOP] gene encoding DNA topoisomerase I is disrupted. This shows that DNA topoisomerase I is the sole target of camptothecin cytotoxicity and illustrates that a nonessential enzyme can nevertheless be the target for a cytotoxic drug.
A variety of antitumor chemotherapeutics have been shown recently to target the DNA topoisomerases (for review, see refs. [1] [2] [3] [4] [5] . Their pharmacological effects correlate well with their effectiveness in trapping a class of complexes between DNA and DNA topoisomerases, termed the cleavable complexes, which are characterized by their conversion to DNAprotein covalent complexes upon their exposure to a protein denaturant (for review, see refs. [6] [7] [8] .
The chain ofevents leading from the trapping ofa cleavable complex to cell death is unclear; it is also uncertain whether the DNA topoisomerases are the sole targets of the drugs. In strains of Escherichia coli lacking the lon protease, the cytotoxicity of antibiotics of the 4-quinolone family, which enhance the formation of a cleavable complex between DNA and DNA gyrase (bacterial DNA topoisomerase II), appear to be related to the induction ofthe SOS repair pathway by these drugs (5, 9) . It is tempting to extrapolate the results obtained in bacterial systems to eukaryotes, given the similarities between bacterial gyrase and eukaryotic DNA topoisomerase II and between the actions ofthe drugs on their respective targets (6) (7) (8) . No suitable eukaryotic genetic system was available, however, for studies of the actions of these drugs.
The budding yeast Saccharomyces cerevisiae appeared to be a natural choice for the genetic dissection of the actions of the topoisomerase-targeting drugs. Purified yeast DNA topoisomerases I and II are very similar to their mammalian counterparts. Although intact cells of ordinary laboratory strains ofthe yeast are refractory to the drugs, our previously unpublished results showed that spheroplasts or cells treated with LiCl according to the procedures commonly used for uptake of DNA are sensitive to treatment with camptothecin (50 ,ug/ml), a plant alkaloid that acts on DNA topoisomerase I (10-12) or 4'-(9-acridinylamino)-methanesulfon-m-anisidide (amsacrine; mAMSA) (100 Ag/ml), an acridine derivative that acts on DNA topoisomerase II (1) (2) (3) (4) (5) . Significantly, the loss of viability of spheroplasts treated with 4'-(9-acridinylamino)-methane-sulfon-o-anisidide (oAMSA) (100 ,g/ml), the ortho analog of mAMSA, which is ineffective as an antitumor agent, was found to be much less. Thus the insensitivity of yeast to the topoisomerase-targeting drugs appeared to be due to a permeability barrier at the cell wall.
Yeast strains have been described previously with pleiotropic drug sensitivity due to enhanced drug permeability (13) (14) (15) (16) . We report in this communication that by the use of suitable yeast permeability mutants, sensitivity to DNA topoisomerase-targeting drugs can be readily seen. In such mutants, both camptothecin and mAMSA, but not oAMSA, induce high levels of homologous recombination and stimulate the expression of a gene DIN3, known to be induced by DNA-alkylating agents and other DNA-damaging agents, including UV light (17, 18) . We show also that all phenotypic changes caused by treatment of these mutants with camptothecin disappear when the mutants were made defective in the expression of DNA topoisomerase I, thus demonstrating that DNA topoisomerase is the sole cellular target of this drug.
MATERIALS AND METHODS
Materials. Yeast strains used in this work are listed in Table  1 . Strain construction was according to standard methods (19) . Various media used in the growth of cells have been described (20) ; YPDAP and YPDAH are YPDA containing 100 mM potassium phosphate, pH 7.5, and Hepes buffer, pH 7.3, respectively. The lactone form of camptothecin appears to be unstable in yeast media at acidic pH. Camptothecin, the lactone form unless indicated otherwise, was purchased from Sigma; mAMSA, oAMSA, and the sodium salt of the acid form of camptothecin were provided by L. F. Liu (Johns Hopkins University, Baltimore, MD). Sodium camptothecin was dissolved in water at 2 mg/ml, and the other drugs were dissolved in dimethyl sulfoxide at 5-10 mg/ml. All other reagents were purchased from commercial sources.
Yeast Transformation and Construction of Gene Disruptions. Yeast transformation was performed by the lithium acetate method (21) . A plasmid-borne LEU2 disruption of yeast topoisomerase I identical to that of Thrash et al. (22) was constructed, and the disruption was used to replace the wild-type TOP] gene by the method of Rothstein (23) . Similarly, rad52 derivatives of CG378 and CG379 strains were constructed using a LEU2 disruption ofthe RAD52 gene (24) . 
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Isolation and Scoring of Drug-Sensitive Strains. The ISE2 mutation was obtained by ethyl methanesulfonate mutagenesis of A364a strain to 5% survival. Mutagenized cells were grown in YPDA medium to allow expression of the induced mutations and then plated on YPDA. They were replica plated to YPDA plates with cycloheximide (0.5-5.0 ,ug/ml). Colonies that grew on YPDA, but not on cycloheximide plates, were tested in liquid medium for sensitivity to aphidicolin (100 pug/ml) (25) . A total of 9 of 20,000 colonies screened were reproducibly sensitive to cycloheximide (0.5-2.0 Ag/ml), of which one (ISE2; see Results) was found sensitive to aphidicolin. Subsequent scoring of ISE2 was done by plating on YPDA plates containing cycloheximide (2.0 ttg/ml) and verified in liquid YPDA containing aphidicolin (100 Ag/ml). The isel mutation was scored on 1.5% agar plates containing YPDA plus crystal violet at 0.5 ,ug/ml or cycloheximide at 0.5-2.0 ,ug/ml. (26) . To score gene conversion at HIS7, cells were plated either directly or after a 10-fold dilution on synthetic medium lacking histidine. In all cases diploids freshly constructed from their haploid parents were used to ensure a low frequency of spontaneous recombination.
Detection of Mutation. Induction of mutation in the CAN] gene by drug treatments was measured by counting the number of colonies on agar plates of synthetic medium lacking arginine but containing canavanine sulfate (50 pug/ml). Mutation induction was also measured from the formation of white colonies in strains carrying ade2-1 mutation. White colonies mainly arise by suppression of the mutation or by a forward mutation in genes the actions of which precede that of ADE2 in the adenine biosynthetic pathway (27) .
Assay of DIN Gene Fusions. Strains carrying a DIN] or a DIN3 fused to the coding sequences of 83-galactosidase at the respective chromosomal location of DIN] or DIN3 were constructed as described by Ruby et al. (17) . Strains carrying these integrated fusions (CG379D1 and CG379D3) were crossed with permeable strains to generate diploids that are heterozygous for the DIN gene fusion. Yeast DIN genes fused to 8-galactosidase were assayed as described (17); reagent blanks were assays with extracts ofdrug-treated cells that do not carry the DIN fusion but are otherwise isogenic.
RESULTS

Permeability Mutants of S. cerevisiae Are Sensitive to
Topoisomerase-Targeting Antitumor Drugs. We have identified yeast strains that are sensitive to the antitopoisomerase drugs camptothecin and mAMSA. Fig. 1A illustrates the effects of mAMSA and oAMSA on the growth of strain JN120. This diploid strain was constructed by mating strain CG379, which is refractory to the drugs, with strain JN127, which is an aphidicolin-sensitive derivative of strain A364a and was found to be sensitive to both mAMSA and camptothecin, but not to oAMSA (data not shown; see Table 1 for a list of all strains). As shown in the figure, sensitivity of JN120 to mAMSA is apparent at drug concentrations as low as 20 tkg/ml, whereas oAMSA has little effect at 100 jug/ml.
The same strain also retains the sensitivity trait of JN127 to camptothecin (data not shown). Because the drug-sensitivity trait in JN127 strain is retained in JN120 strain and is therefore dominant, we tentatively designated the gene for this trait ISE2, and its inhibitor-resistant counterpart ise2. Fig. 1B illustrates the effect of camptothecin on the growth of strain FL599, which carries an inhibitor-sensitive recessive mutation isel (15) . The mutation isel was initially identified as one that confers recessive sensitivity to crystal violet (0.5 ,ug/ml) or cycloheximide (0.5 pug/ml). As shown in the figure, the strain is also highly sensitive to camptothecin; inhibition of cell growth is noticeable at a drug concentration as low as 5 ,ug/ml, and killing of cells is seen at a dose of 50 ,ug/ml (Fig. 1B) or higher (data not shown) . In contrast to strain JN120 (ISE2), which is sensitive to both camptothecin and mAMSA, strain FL599 (isel) is insensitive to mAMSA at doses to 100 ,g/ml.
DNA Topoisomerase-Targeting Antitumor Drugs Induce High Levels of Recombination in Drug-Sensitive Mutants. Treatment of drug-sensitive mutants with mAMSA and camptothecin causes an increase in the level of recombination. We examined crossing over induced by the drugs by the use of the red/white colony test for homozygosis at adel or ade2 (ref 27; see also Materials and Methods). As shown in Table 2 , treatment of JN173 (ise2/ISE2; adel-2/ADEJ) cells with mAMSA or camptothecin resulted in a large increase in red and red-sectored colonies; a large increase was also seen upon treatment of an (ade2/ADE2; isel/isel) diploid strain JN388 with camptothecin. Treatment of JN173 with oAMSA (100 pig/ml), on the other hand, showed essentially no effect on the number of red or red-sectored colonies.
Because formation of red or red-sectored colonies by homozygosis in diploid strains can arise by chromosome loss as well as by recombination, we also examined induction of gene conversion by the drugs. As shown in Table 2 , treatment of strain JN173 (ise2/ISE2; his7-2/his7-n) with mAMSA or camptothecin increases greatly the frequency of His + colonies. There is considerable spread in data obtained in different experiments with mAMSA; typically a 5-to 20-fold increase was seen upon incubation of cells with 50 ,g of the drug per ml for 24 hr. When cells ofthis strain were incubated with oAMSA (100 ,ug/ml) for 24 hr, the increase of His+ colonies over the no-drug control was not > :'2-fold and was not significantly different from the no-drug control. We also examined the dependence of the number of His + colonies on mAMSA concentration. Upon incubation ofthe cells with the drug for 24 hr, the number of His+ colonies per 106 viable cells was measured to be 4.1, 4.0, 7.3, 14, and 25, respectively, at 5, 10, 20, 50, and 100 ,ug of the drug per ml. When JN173 cells were incubated with sodium camptothecin (50 ,g/ml) for 24 hr, a 50-fold increase in His+ colonies was seen. For both mAMSA and sodium camptothecin, treatment with low doses of each drug resulted in an increase in the absolute number ofrecombinants as well as an increase in the frequency of convertants (data not shown).
The effect of camptothecin on mutation frequencies is minor. Treatment of JN127 (CAN1) with camptothecin (50 ;kg/ml) for 8 hr, for example, resulted in a 4-fold increase in the number ofcanavanine-resistant colonies due to mutations in the CANI gene encoding arginine permease. Similar treatment of the haploid strain JN384T1 (ade2), which forms red colonies on YPDA plates, increased 5-fold the number of white colonies due to mutations that suppress ade2 or mutations in one of the genes preceding ADE2 in the adenine biosynthetic pathway (27) . Thus the high level of red colonies and histidine prototrophs produced by camptothecin are produced mainly by recombination. Nonetheless, both mAMSA and camptothecin appear to act as weak mutagens.
A DNA Damage-Inducible Gene DIN3 Is Induced by Camptothecin or mAMSA in Yeast Strains Sensitive to the Drug. Several DNA damage-inducible genes have been identified by Ruby and Szostak (18) by joining the promoters of these genes, termed the DIN genes, to the coding sequences of /3-galactosidase. We have tested two such DIN-/3-gal fusions, DIN] and DIN3. Fig. 2 shows that in the strain JN173, either camptothecin or mAMSA induces DIN3. The maximal level of 8-galactosidase induction by camptothecin or mAMSA in JN173 compares with that induced by treatment with 0.01% methyl methanesulfonate. The analog of mAMSA, oAMSA, has little effect on the expression of ,3-galactosidase. When the same experiments were done with strain JN120, which is isogenic with JN173 except that it carries a DIN-/3-gal rather than a DIN3-/3-gal fusion, no increase in the 83-galactosidase level was ever seen. JN173 cells were treated as described with mAMSA, oAMSA, or sodium camptothecin. Homozygosis of ade2 in camptothecin-treated cells was done with strain JN388. Roman numerals refer to separate experiments with independently constructed diploids. Reciprocal exchange was scored by examining YPDA plates for red or red-sectored colonies. The reds include all colonies with either one-half or one-fourth red sectors and do not include colonies with smaller sectors. Gene conversion in his7 was scored by plating on agar plates containing a synthetic medium lacking histidine; the frequency of His' was obtained by comparing viable titers on "histidine-dropout" plates and YPDA plates. 
Sensitivity of Permeable Yeast Cells to Camptothecin Is
Much Enhanced by the Introduction of rad52 Mutation. Because camptothecin is a potent inducer of recombination, it appeared likely that genes involved in repair and recombination might be important in the cellular response to the drug. As illustrated in Fig. 3 , the strain JN60-5, which is a congenic radS2 derivative of strain JN57-10 (ise) RADS2) is much more sensitive to the drug.
DNA Topoisomerase I Is the Sole Cellular Target of Camptothecin. When mutations inactivating DNA topoisomerase I were introduced into strains that are sensitive to camptothecin, the cells became resistant to the drug. In one experiment, strains JN284 and JN362 (isel leu2 TOP)) were transformed to Leu2+ top) by the one-step gene replacement method (23) , and five transformants of each were grown and tested for sensitivity to camptothecin. It was found that 85 ± 6% and 89 + 9t% of the top) cells survived incubation with camptothecin (50',g/ml) for respectively. For the TOP) + controls, which are identical to the respective mutants except that in each control a copy of the TOP) gene on a single-copy plasmid YCp5O (28) had been introduced, the corresponding values were 9 and 17 + 4%. Inactivation of DNA topoisomerase I in a camptothecinsensitive strain not only suppresses the drug sensitivity, it also eliminates all other phenotypes of the drug-treated cells described earlier. When a diploid strain constructed by mating JN85 ADE) top) and JN84 ade) top) was tested for ADE) homozygosis upon treatment with sodium camptothecin (50 ug/ml) for 24 hr, 0.07% of the cells were scored as red colonies; this value is not significantly different from that of untreated control cells, which gave 0.1% red colonies. In contrast, when the TOP) + strain JN85 (ADE) TOP)) x JN84 (adel TOP]) was used, 1.4% of the drug-treated cells gave red colonies compared with 0.03% red colonies for the untreated cells.
A similar series of experiments were done for the effects of incubation with camptothecin (50 pug/ml) on homozygosis at ADE2, using the strains JN386 x JN62-3 (ADE2 topl/ade2-1 top)) and its isogenic hr, respectively,' which are not significantly higher than the corresponding values for control cells incubated in the absence of the drug, 0.07% and <0.05%. The effect of inactivation of DNA topoisomerase I on the induction of DIN3 by camptothecin is shown in Fig. 4 Proc. Nati. Acad. Sci. USA 85 (1988) 7505 advantage of using a genetically tractable model in the dissection of physiologically complex phenomena has been well-recognized. Biochemical studies with mammalian DNA topoisomerase I (10, 11) and the finding that the enzyme purified from a clonal line of human lymphoblastic leukemia cells is resistant to camptothecin (12, 29) have provided strong evidence that DNA topoisomerase I is a cellular target of the alkaloid. It is difficult to show in a mammalian system, however, that the enzyme is the only target of the drug. With the yeast system, experiments with the appropriate mutants show clearly that this is the case. Our results with the yeast mutants demonstrate further a unique aspect of the DNA topoisomerases as targets of therapeutic agents: a nonessential topoisomerase such as yeast DNA topoisomerase I can be the sole target of a cytotoxic drug. In this connection, it is noteworthy that bacterial and viral topoisomerases, whether they are essential or not, could serve as targets of antibiotics and antiviral agents (31) (32) (33) .
Our results lend further support to the notion that in eukaryotes DNA topoisomnerase II is the target of mAMSA. Because of the indispensability of DNA topoisomerase II, whether the enzyme is the sole target of a drug cannot be readily tested by the use of null mutants. The inference is, therefore, based on the differences in the physiological effects of mAMSA and its analog oAMSA. The isolation of drug-resistant top2 mutants should provide an unequivocal conclusion.
It is interesting that in yeast mutants sensitive to camptothecin and mAMSA, the two drugs elicit similar physiological responses. These similarities could be attributed to the parallel roles of DNA topoisomerases I and 11 (30) or to the common denominator of the drugs in their trapping of the cleavable complexes. Studies of the topoisomerase-targeting drugs also illustrate clearly that the DNA topoisomerases are an important link between the actions of a diverse spectrum of compounds and the genetic stability of a cell. In mammalian systems, it has been shown that both camptothecin and DNA topoisomerase II-targeting antitumor drugs induce chromosomal aberrations (1) (2) (3) (4) (5) . The findings discussed in the Results section demonstrate that yeast should be a valuable system for the dissection of the mechanisms of processes leading to genetic instability in eukaryotes.
